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ABSTRACT
Objectives To analyse enrolment to interventional 
trials during the first wave of the COVID-19 pandemic 
in England and describe the barriers to successful 
recruitment in the circumstance of a further wave or 
future pandemics.
Design We analysed registered interventional COVID-19 
trial data and concurrently did a prospective observational 
study of hospitalised patients with COVID-19 who were 
being assessed for eligibility to one of the RECOVERY, C19- 
ACS or SIMPLE trials.
Setting Interventional COVID-19 trial data were analysed 
from the  clinicaltrials. gov and International Standard 
Randomized Controlled Trial Number databases on 12 July 
2020. The patient cohort was taken from five centres in a 
respiratory National Institute for Health Research network. 
Population and modelling data were taken from published 
reports from the UK government and Medical Research 
Council Biostatistics Unit.
Participants 2082 consecutive admitted patients with 
laboratory- confirmed SARS- CoV-2 infection from 27 March 
2020 were included.
Main outcome measures Proportions enrolled, and 
reasons for exclusion from the aforementioned trials. 
Comparisons of trial recruitment targets with estimated 
feasible recruitment numbers.
Results Analysis of trial registration data for COVID-19 
treatment studies enrolling in England showed that 
by 12 July 2020, 29 142 participants were needed. 
In the observational study, 430 (20.7%) proceeded to 
randomisation. 82 (3.9%) declined participation, 699 
(33.6%) were excluded on clinical grounds, 363 (17.4%) 
were medically fit for discharge and 153 (7.3%) were 
receiving palliative care. With 111 037 people hospitalised 
with COVID-19 in England by 12 July 2020, we determine 
that 22 985 people were potentially suitable for trial 
enrolment. We estimate a UK hospitalisation rate of 2.38%, 
and that another 1.25 million infections would be required 
to meet recruitment targets of ongoing trials.
Conclusions Feasible recruitment rates, study design 
and proliferation of trials can limit the number, and size, 
that will successfully complete recruitment. We consider 
that fewer, more appropriately designed trials, prioritising 
cooperation between centres would maximise productivity 
in a further wave.
INTRODUCTION
Unless a successful vaccination programme 
is deployed, the greatest need for COVID-19 
Strengths and limitations of this study
 ► We comprehensively analysed clinical trial registry 
data to quantify the number of participants required 
to successfully complete enrolment to interventional 
COVID-19 trials based in England in the first wave of 
the pandemic.
 ► We simultaneously performed a large, prospective, 
observational cohort study of 2082 people hospi-
talised with COVID-19 to report recruitment rates 
across a range of secondary and tertiary centres and 
characterise reasons for trial exclusion.
 ► Using government data on COVID-19 hospitalisa-
tions, we consider the differences between the trials 
community’s aspirations and delivery, and how this 
might inform our strategy in the event of a second 
wave.
 ► Our analysis is restricted to two registry databases 
and includes trials that started recruiting late in the 
first wave; we therefore likely underestimate the 
recruitment target and overestimate the number of 
eligible patients.
 ► Our analysis is limited to data based in England and, 
while we consider global trials, our conclusions may 
not be representative of, or readily translatable to, 
international cohorts.
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remains effective treatments. This presents a substantial 
challenge. Ostensibly, the response from the experi-
mental medicine community to the first wave has been 
robust, with >1970 clinical trials planned, recruiting or 
completed, at the time of writing.1 This has enabled 
enrolment of patients to trials of drugs with known safety 
profiles—including lopinavir,2 remdesivir,3 4 hydroxy-
chloroquine5 6 and tocilizumab7—and led to posi-
tive results, such as the 12.1% absolute risk reduction 
in mortality among ventilated patients treated with 
dexamethasone.8
However, while many of these trials have been prag-
matic in terms of selection criteria, the proportion of 
hospitalised patients with COVID-19 being recruited 
to clinical trials is lower than might have been antici-
pated; the authors of the RECOVERY trial recently esti-
mated a 10% recruitment rate in the UK.9 Meanwhile, 
in areas where public health measures have limited viral 
transmission, trials have terminated early on account of 
under- recruitment.10 11 With mounting concern about 
an ensuing second wave of infection,12 13 it is increasingly 
important to learn lessons from the first, and consider the 
number, size and design of clinical trials that can feasibly 
be completed.
We hypothesised that the proliferation of SARS- CoV-2 
interventional studies during the pandemic and under 
recognised barriers to recruitment of patients with 
COVID-19 led to unachievable recruitment targets in 
England. We used data from clinical trial registry data-
bases to quantify recruitment targets and concurrently 
studied recruitment rates, including reasons for exclu-
sion, across five centres enrolling patients at the peak 
of the first wave of the pandemic. In conjunction with 
publicly available data from the UK government, we 
consider the differences between the trials community’s 
aspirations and delivery, and how this might inform our 
strategy if there were a second wave.
METHODS
Establishing recruitment targets for registered trials during 
first wave
COVID-19 clinical studies registered on  clinicaltrials. gov 
or the International Standard Randomized Controlled 
Trial Number (ISRCTN) databases were identified and 
study data downloaded on 12 July 2020. Data for trials 
based in England, multinational trials with centres 
in England and global trials were extracted in turn. 
Cross- registered studies were identified and accounted 
for once in the analysis. A manual review determined 
whether sponsors were academic, non- academic or 
mixed. Trials were excluded if they were labelled as 
terminated, withdrawn or suspended. Data for interven-
tional trials examining treatment and prevention were 
documented, but only trials of COVID-19 treatments 
were used in the analysis. Analyses were performed 
using RStudio V.1.2.5042.
Observational study of recruitment of hospitalised patients
We performed a prospective observational study of 2082 
consecutive patients with SARS- CoV-2 infection at five 
hospitals affiliated to the National Institute for Health 
Research- Translational Research Collaboration with 
representation from secondary and tertiary centres: 
Cambridge University Hospitals NHS Foundation Trust 
(CUHFT), Cambridge; Imperial College Healthcare, 
University College Hospital and King’s College Hospi-
tals, London and University Hospital of North Tees, 
Middlesbrough. Subjects were admitted and eligibility 
assessed for: RECOVERY (ISRCTN50189673), C19- 
ACS (NCT04333407) or SIMPLE (NCT04292730/
NCT04292899). CUHFT local R&D approval was 
undertaken.
Demographic and clinical data were collected by 
contemporaneous review of potential participants’ 
case notes. A categorical approach subdivided primary 
reasons subjects were not enrolled into: (a) clinical 
grounds (screening or treating physician judgement 
that comorbidity or other reason for admission was more 
critical to patient outcome than COVID-19), (b) medi-
cally fit for discharge, (c) receiving end- of- life care, (d) 
lack of capacity, (e) patient refusal, (f) interactions with 
trial drugs or (g) already on mechanical ventilation. 
Although already being on mechanical intervention 
was not an exclusion criterion for RECOVERY, patients 
categorised as excluded on these grounds were ineli-
gible on account of competing, intensive care- based, 
studies.
Establishing feasible recruitment for registered trials during 
first wave
Using publicly available UK government data of the 
numbers of patients with COVID-19 admitted to English 
hospitals during the first wave between 17 March and 5 
August 2020,14 and the recruitment rate (with 95% CI for 
one sample proportion with continuity correction) from 
the aforementioned observational study, we estimated a 
maximum bound for the accumulated feasible recruit-
ment during that time. Simultaneously, we used the esti-
mated cumulative number of infected cases in England 
by 12 July provided by Medical Research Council (MRC) 
Biostatistics Unit at the University of Cambridge15 to 
calculate an approximate hospitalisation rate in England 
among COVID-19 infections. We based our estimates on 
data from centres in England as the infection rate esti-
mates were more reliable, hospitalisation criteria were 
different in Wales14 and the five hospitals included in this 
study are all from England.
Patient and public involvement
This was a time- critical study in response to a Public 
Health Emergency of International Concern. Patients or 
the public were not involved in the design, conduct or 
reporting of this research.
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RESULTS
Establishing recruitment targets to registered trials during 
first wave
Clinical trial registry data were downloaded on 12 July 
2020; 28 interventional studies were included in our 
analysis of those registered in England. Twenty- two 
(78%) were academically sponsored, 5 (18%) were 
non- academically sponsored and 1 (4%) was mixed. 
The first registration date of a COVID-19 treatment 
trial in England was 22 March; the earliest registered 
start date was 12 March. Analysis of recruitment targets 
for each trial revealed that 46 154 participants would 
be required to complete recruitment to all studies in 
England (table 1): 17 012 people are required for trials 
of prophylactic drugs to prevent COVID-19, while 29 142 
are needed for those treating established COVID-19 
(table 1). The median (IQR) treatment trial recruitment 
target was 195 (50–793).
By contrast, the global situation is such that 1107 regis-
tered interventional trials were ongoing or completed, 
requiring 566 872 patients to be randomised to allow 
their completion; 306 426 of these are needed for trials 
of COVID-19 treatments (figure 1A,B). These trials are 
geographically clustered in China, North America and 
Europe (figure 1C).
Observational study of clinical trial enrolment
From 27 March to 22 May 2020, a total of 2082 consecutive 
patients were included across the five sites (table 2). Age 
and sex data were available for 1971 patients: the median 
(IQR) age was 71 (58–82) and 56.2% were male. Across 
the four trials, 430 (20.7%, 95% CI 18.95% to 22.47%) 
proceeded to randomisation.
Table 1 Summary of number of trials and required 
numbers of participants
Number of trials Number of participants
Global trials
  Prevention 172 260 446
  Treatment 935 306 426
  Total 1107 566 872
UK multinational and national trials
  Prevention 11 97 272
  Treatment 38 44 362
  Total 49 141 634
England trials
  Prevention 8 17 012
  Treatment 20 29 142
  Total 28 46 154
Figure 1 The proliferation of global clinical trials in response to COVID-19. (A) Cumulative number of enrolling studies 
registered with clinicaltrials.gov or International Standard Randomized Controlled Trial Number until 12 July 2020, subdivided by 
those testing drugs for COVID-19 treatment and prevention. (B) Cumulative number of participants required to meet recruitment 
targets for registered clinical trials. (C) Geographical distribution of COVID-19 clinical trials.
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Of the remaining 1652 patients, 82 (3.9%) declined 
participation, 363 (17.4%) were medically fit for discharge, 
153 (7.3%) were receiving end- of- life care and 106 (5.1%) 
were mechanically ventilated at the time of screening. In 
699 (33.6%) patients, the screening or treating physician 
determined that the potential participant should not be 
enrolled on account of clinical grounds or trial exclusion 
criteria.
Establishing feasible recruitment for registered trials during 
first wave
By combining these observed recruitment rates with 
publicly reported hospitalisation data (between 17 March 
and 12 July 2020), we estimated a maximum upper bound 
for the accumulated feasible recruitment for registered 
trials of COVID-19 treatments in England during the first 
wave (figure 2A,B).
The estimated number of cumulative infected cases by 
12 July reported by MRC Biostatistics Unit is 4.67 million 
with a 95% credible interval (3.76 to 6.04). Combined 
with the number of cumulative admitted patients in 
England by 12 July from government data (ie, 111 037 
hospital admissions), this gives an approximate hospital-
isation rate 2.38% (1.84% to 2.95%) in England during 
the first wave.
Our analysis indicates that by 12 July, 6158 patients 
might still be needed to meet the total recruitment 
targets for currently recruiting clinical trials. If consid-
ering uncertainty in recruitment rate estimate reflected 
by 95% CI (18.95% to 22.47%), 4192–8100 patients might 
be required to meet recruitment target. Assuming the 
recruitment rate 20.7%, this implies that 29 749 hospital-
ised patients would need to be screened for these trials to 
complete recruitment. With the approximate hospitalisa-
tion rate 2.38% in England as observed in the first wave, 
this would require 1.249 million patients to be infected.
With the daily infection rate for UK estimated to be 
3310 (95% credible interval (2440 to 4460)) on 12 July,15 
it is highly unlikely such a large number of hospitalisa-
tions would occur unless there is an increase in the infec-
tion numbers (or a second wave). Indeed, incorporating 
hospitalisation data to 5 August 2020 shows minimal 
progress towards the recruitment target, assuming no 
new trials were approved after 12 July 2020 (figure 2A,B).
DISCUSSION
We found that the proliferation of clinical trials1 in 
response to the first wave of the COVID-19 pandemic in 
England required 29 142 participants to complete enrol-
ment to those registered with a trials database. Globally, 
306 426 participants are required to meet recruitment 
targets for trials of treatments of COVID-19. Meanwhile, 
in our multicentre prospective observational cohort 
study of patients admitted to hospital with laboratory- 
confirmed COVID-19, 79.3% of potential participants 
were not recruited to a clinical trial; the reasons for 
excluding patients were varied and clarify the challenges T
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faced in both general hospitals and well- resourced 
centres experienced in experimental medicine. Our 
experience is consistent with the general literature on 
clinical trial recruitment where many factors have been 
posited to contribute to heterogeneity of recruitment.16 
With 111 037 people hospitalised in England between 17 
March and 12 July 2020, our net recruitment rate suggests 
that 22 985 (21 042–24 950 if taking into account uncer-
tainty in recruitment rate estimate by random errors) 
would have been potentially suitable for selection in 
the first wave. However, this is clearly an overestimate, 
given that it would require each of these individuals to 
be hospitalised in geographical locations where medical 
centres were undertaking these trials. In the first wave, 
most general clinical trials infrastructure was mothballed 
for normal activity and therefore easily seconded towards 
COVID-19 and this may not be the case in subsequent 
‘waves’. It must also be recalled that most recruitment in 
the first wave was undertaken as hospitals were actively 
reconfiguring services. A stable hospital infrastructure 
may positively impact on ease of delivery in the future. 
Nevertheless, unless there is a second wave it is highly 
unlikely that the total recruitment target will be met in 
any reasonable timeframe.
Strengths of our study are that our analyses of registry 
and population databases used the largest and most 
robust data available. Meanwhile, our observational study 
applied a large cohort size, prospective data acquisition 
and recorded detailed reasons for excluding patients. By 
using both secondary and tertiary care centres, we believe 
our results are generalisable to other hospitals in the UK. 
Also, by following studies with minimal selection criteria, 
particularly in the RECOVERY trial, we reduced the 
chance of underestimating trial recruitment. Our study 
does have limitations. First, our predictions were based 
on registry data for studies based in England alone; we 
did not include the numbers of participants required to 
be recruited into multinational trials in which the English 
centres were involved. The result is that we have likely 
underestimated the trial recruitment target for England 
and, by extension, the gap between this and the number 
of participants available. Second, although we used hospi-
talisation data from 17 March 2020, as this was the time 
the UK government commenced public reporting of 
COVID-19 admissions, all trials included in our registry 
analysis were not recruiting at that stage; the earliest start 
date for a trial registered in England was 12 March 2020, 
but the last trial start date was not until 7 July 2020. In this 
sense, using cumulative number of admitted patients in 
our prediction is optimistic. Third, we only included the 
two registry datasets in most widespread use, and so may 
have further underestimated the number of studies and 
participants required. Fourth, the 95% CI for recruitment 
rate estimate only reflects the uncertainty due to random 
errors in the data, it does not consider the uncertainty 
due to unrepresentativeness of data from the five hospital 
centres in our study. Finally, although we illustrate the 
scale of trial recruitment required globally, the popula-
tions tested may not be representative of, or translatable 
to, international cohorts.
Our study is the first to characterise the suitability 
and barriers for trial enrolment for a complete cohort 
of hospitalised patients with COVID-19. Results of trials 
published to date convey a different message: interven-
tional studies of lopinavir and remdesivir, for example, 
have recruitment rates ranging from 55.7% to 96.0%.2–4 
This difference is most likely explained by the different 
denominators used in our calculations: the consort 
Figure 2 Feasibility of achieving target recruitment in England for COVID-19 interventional studies. (A) Cumulative number of 
enrolling studies in England registered with clinicaltrials.gov or International Standard Randomized Controlled Trial Number until 
12 July 2020, subdivided by those testing drugs for COVID-19 treatment and prevention. (B) Cumulative number of participants 
required to meet recruitment targets for registered COVID-19 treatment trials until 12 July 2020, and predicted number of 
patients who would have been eligible for randomisation (grey shaded area represents point- wise 95% confidence band for the 
predictive cumulative number of eligible patients using the lower and upper value of 95% CI for the recruitment rate estimate 
with continuity correction). The reduction in the infection rate in England means that the recruitment target at 12 July is unlikely 
to be reached unless there is a second wave; further illustrated by extending hospitalisation data to 5 August 2020.
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diagrams in clinical trials are unlikely to include every 
single patient hospitalised with a positive test. Instead, 
our results align with or exceed other centres, such as 
the 10% recruitment rate to RECOVERY.9 During the 
2013–16 Ebola Virus Disease epidemic in west Africa, 
most clinical trials during that crisis either started too late 
to enrol sufficient case numbers or were simply unable 
to reach their recruitment targets.17 Our study shows 
that trials in England started recruiting relatively quickly, 
however many are highly unlikely to recruit on time; we 
conclude that starting early is important but not enough 
to ensure recruitment targets are met. Finally, it is notable 
that our calculated hospitalisation rate of 2.38% is lower 
than that observed in Wuhan,18 which if applied to the 
UK age structure,19 is equivalent to approximately 5.8%.
The disparity between the realistic recruitment rates 
and high requirements we report leads us to conclude that 
the scientific community should be increasingly selective 
in the number, size and design of clinical trials deployed 
in the COVID-19 pandemic; our findings have meaning 
for those planning single trials, and those strategising the 
national response. Potential solutions include practical 
changes to trial design, for instance, capturing patients 
earlier in their disease path, and adopting dynamic and 
adaptive trial designs.20 Yet, such measures are unlikely 
to bridge the currently estimated large recruitment gap. 
Instead, it may be necessary for healthcare authorities 
and policy makers to foster more academic coopera-
tion to prioritise compounds, prevent duplication and, 
perhaps more radically, perform real- time meta- analyses 
of ongoing trials of the same therapies and provide stop/
go recommendations across trials to rationalise treat-
ment and prevent multiple studies delaying reporting.21 
Indeed, proposals have been forthcoming for mecha-
nisms by which data from different trials might be shared 
and analysed in a robust and scientifically meaningful 
way.22 These conclusions are not dissimilar to reflections 
from the Ebola pandemic, when there was a strong call 
for strengthening and coordinating research efforts in 
response to outbreaks of emerging infectious diseases.23 24 
For planning future trials and deriving realistic recruit-
ment targets, real- time tracking of the pandemic, as 
data accumulate over time, is essential to plan research 
in response of an emerging epidemics outbreak. The 
MRC Biostatistics Unit regularly nowcast and forecast 
COVID-19 infections and deaths.15 This information 
feeds directly to SAGE subgroup, Scientific Pandemic 
Influenza subgroup on Modelling and to regional Public 
Health England teams. These same data could be used to 
establish realistic recruitment trends to inform, monitor 
and coordinate research efforts both for treatment and 
prevention trials.
Multiple questions remain for future research. In 
particular, it remains unclear how relaxing of non- 
pharmacological interventions will affect transmission 
rates, and therefore the achievability of remaining recruit-
ment to these trials. It is also unknown how a second wave 
would evolve, and whether more or fewer people will 
develop the illness than was seen in the first. Nonetheless, 
we conclude that clinical trialists and healthcare author-
ities must consider the recruitment challenges when 
determining the feasibility of clinical trials in a second 
wave and urgently rationalise those currently active.
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